| Multiple Sclerosis |
1 |
1 |
| Antiviral Agents |
0 |
0.67 |
| Infectious Mononucleosis |
0 |
0.43 |
| Epstein-Barr Virus |
0 |
0.99 |
| Myelin |
0 |
0.33 |
| Child |
0 |
0.25 |
| Antigens |
0 |
0.17 |
| Central Nervous System |
0 |
0.17 |
| Clinical Research |
0 |
0.17 |
| Disease-Modifying Therapy |
0 |
0.17 |
| Multiple Sclerosis Risk |
0 |
0.17 |
| Vaccines |
0 |
0.13 |
| Biologic Therapy |
0 |
0.12 |
| Tumor Genetics |
0 |
0.12 |
| Herpes Simplex |
0 |
0.09 |
| Influenza |
0 |
0.09 |
| Adhesion |
0 |
0.08 |
| Allergy |
0 |
0.08 |
| Blood |
0 |
0.08 |
| Cancer |
0 |
0.08 |
| Fellowship |
0 |
0.08 |
| Fever |
0 |
0.08 |
| Genetics |
0 |
0.08 |
| Hospital |
0 |
0.08 |
| Immunization |
0 |
0.08 |
| Immunology |
0 |
0.08 |
| Immunosuppressive Therapy |
0 |
0.08 |
| Lymphoma |
0 |
0.08 |
| Massachusetts |
0 |
0.08 |
| Match |
0 |
0.08 |
| Multiple Sclerosis Treatment |
0 |
0.08 |
| Tumor |
0 |
0.08 |